Hospira is voluntarily recalling three lots of the injectable opioid medication Hydromorphone HCl because the glass vials may be broken or cracked, the Food and Drug Administration announced yesterday. Hospira has notified hospitals and others with an existing inventory of the lots subject to this recall that they should stop use and distribution of the remaining units and quarantine them immediately. See the FDA announcement for more information, including the lot numbers. Health care professionals are encouraged to report any related problems or events to the FDA's MedWatch Program. Last week, the AHA and others asked the Drug Enforcement Administration to temporarily adjust the aggregate production quotas for certain injectable opioid medications in short supply to allow other manufacturers to supply product until the shortages resolve.
 

Related News Articles

Headline
The Centers for Disease Control and Prevention June 25 issued a Health Alert Network Health Advisory about an increased risk of dengue virus infections in the…
Headline
“Safety Speaks” is a new Advancing Health series where hospital and health system leaders share successes from their organizations’ patient safety efforts. In…
Blog
The Meharry School of Global Health is the realization of a promise made by Meharry Medical College almost 150 years ago — a promise born out of the legacy of…
Headline
As part of Community Health Improvement Week June 10-14, the AHA released a video showcasing the impact Indiana University Health's iHEART collaborative has…
Headline
The AHA June 7 submitted comments on a discussion draft of the Drug Shortage Prevention and Mitigation Act, bipartisan legislation proposing to provide…
Headline
The AHA announced June 5 that Main Line Health in Radnor, Pa., Augusta Health in Fishersville, Va., and AnMed in Anderson, S.C., are the three honorees for…